Evidence map›Paper›PMID 41047476›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post-Operative Osteosarcoma Treatment.

Yilong Dong, Lingshuang Wang, Hui Zhang, Menghuan Li, Zhong Luo, Yan Hu, Chunyuan Cai

Abstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yilong DongRuian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325200, China.
Lingshuang WangSchool of Life Sciences, Chongqing University, Chongqing, 400044, China.
Hui ZhangDepartment of Breast, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400021, China.
Menghuan LiSchool of Life Sciences, Chongqing University, Chongqing, 400044, China.
Zhong LuoSchool of Life Sciences, Chongqing University, Chongqing, 400044, China.
Yan HuCollege of Bioengineering, Chongqing University, Chongqing, 400044, China.ORCID https://orcid.org/0000-0001-7133-8525
Chunyuan CaiRuian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325200, China.

Funding

Chongqing Municipal Science and Technology Bureau CSTB2022NSCQ-MSX0488Chongqing Municipal Science and Technology Bureau CSTB2023NSCQ-MSX3661Fundamental Research Funds for the Central Universities 2023CDJYGRH-ZD01Fundamental Research Funds for the Central Universities 2024CDJYXTD-008Key Technologies Research and Development Program 2022YFB3804400National Natural Science Foundation of China 32471457National Natural Science Foundation of China 52333011National Natural Science Foundation of China 52471261Zhejiang Medical Association 2024KY398
6 · The paper itself

Abstract

Surgery is a mainstream treatment of osteosarcoma in the clinic, which often causes critical-size bone defects due to its highly invasive nature. However, the post-operative osteosarcoma management still remains challenging, characterized by high risks of recurrence and insufficient defect recovery. Recent studies increasingly reveal that the osteoimmune system is a crucial mediator of bone homeostasis and immune protection functions, emerging as a crucial nexus linking the antitumor immunity and osteopromotion regimes. Consequently, there is significant interest to develop new strategies to modulate the immune responses in the post-operative defect site, aiming to sustainably inhibit residual tumor growth and recurrence while accelerating defect regeneration. Interestingly, orthopedic implants emerge as optimal platforms for the on-demand engineering of immune responses in the post-operative defects in a highly integrative approach. Herein, a comprehensive review is provided on the principles and designs of osteoimmunomodulatory orthopedic implants for evoking osteosarcoma-specific immunity while boosting osseointegration and bone defect recovery. Overall, osteoimmunomodulatory orthopedic implants offer immense potential for ameliorating the osteosarcoma treatment outcome by improving patient survival and quality of life.

Indexed as

Bone NeoplasmsOsteosarcomaProstheses and ImplantsAnimalsHumansOsseointegrationbone defect healingorthopedic implantsosteoimmune systemosteosarcoma immunotherapypost‐operative osteosarcoma treatment

Identifiers

PMID41047476
PMCPMC13292201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.